|
|
||||||||
University of Minnesota Hospitals, Minneapolis, Minnesota
Correspondence: For reprints contact: Timothy E. Tully, Div. of Nuclear Medicine, University Hospitals, Box 382, Mayo Memorial Bldg., Minneapolis, Minn. 55455.
ABSTRACT
The use of 32P-chromic phosphate in glucose suspension for intracavitary radiotherapy is complicated by the fact that the distribution of the particulate suspension after installation is unknown. The simultaneous administration of 99mTc-sulfur coiloid with the radiopharmaceutical followed by imaging of the appropriate cavity will depict accurately the distribution of the injected colloid. If one assumes that the two agents initially will occupy the same space and are distributed in a similar fashion, an estimation of the distribution of chromic phosphate is possible.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |